Journal Information
Vol. 41. Issue 5.
Pages 255-259 (May 2005)
Share
Share
Download PDF
More article options
Vol. 41. Issue 5.
Pages 255-259 (May 2005)
Original Articles
Full text access
Lung Transplant Therapy for Suppurative Diseases
Visits
3939
A. de Pablo
Corresponding author
alic1575@separ.es

Correspondence: Dr. A. de Pablo. Servicio de Neumología. Clínica Puerta de Hierro. San Martín de Porres. 28035 Madrid. España
, S. López, P. Ussetti, M.C. Carreño, R. Laporta, C. López García-Gallo, M.J. Ferreiro
Servicio de Neumología, Clínica Puerta de Hierro, Madrid, Spain
This item has received
Article information
Abstract
Bibliography
Download PDF
Statistics
Objective

Lung transplantation is a valid therapeutic approach for patients with bronchiectasis. The objective of the present study was to evaluate our experience with bronchiectasis patients and compare the results in patients with cystic fibrosis to results in those with bronchiectasis caused by other processes.

Patients and methods

We carried out a retrospective study of bronchiectasis patients treated by lung transplantation in order to analyze demographic, functional and microbiological characteristics before and after transplantation, and survival.

Results

From 1991 to 2002 lung transplants were performed on 171 patients, 44 of whom had suppurative lung disease (27 had cystic fibrosis and 17 had bronchiectasis caused by other processes). There were no significant differences in the demographic variables between the 2 groups. At transplantation, lung function variables showed severe bronchial obstruction (mean [SD] forced expiratory volume in 1 second of 808 [342] mL and forced vital capacity of 1390 [611] mL) and respiratory insufficiency (PaO2 at 52 [10] mm Hg and PaCO2 at 48 [9] mm Hg). Only PaO2 was significantly lower in patients with bronchiectasis from causes other than cystic fibrosis. Airway colonization was present in 91% of the patients; Pseudomonas spp germs were detected in 64% of the cases and were multiresistant in 9%. In the early postoperative period germs were isolated in 59% of the cases, half of which involved the same germ as had been isolated before transplantation. One year after lung transplantation, 34% of the patients continued to have bronchial colonization. Survival at 1 year was 79% and at 5 years, 49%, with no significant difference between the patients with cystic fibrosis and those with other suppurative diseases, nor between the patients with and without Pseudomonas colonization. Only 2 patients had died of bacterial pneumonia at 1 month after transplantation.

Conclusions

Although airway colonization in patients with suppurative diseases complicates postoperative management, the results in terms of survival are good.

Key Words:
Lung transplantation
Bronchiectasis
Cystic fibrosis
Pseudomonas
Suppurative lung disease
Objetivo

El trasplante pulmonar es una opción terapéutica válida para pacientes con bronquiectasias. El objetivo de nuestro trabajo ha sido analizar nuestra experiencia en estos pacientes y comparar los resultados entre los pacientes con fibrosis quística y bronquiectasias de otra etiología.

Patientes y métodos

Se ha realizado un estudio retrospectivo de los pacientes trasplantados por bronquiectasias para analizar las características demográficas, funcionales y aspectos microbiológicos antes y después del trasplante, así como la supervivencia.

Resultados

Entre 1991 y 2002 trasplantamos a 171 pacientes, de los cuales 44 presentaban enfermedad pulmonar supurativa (27 fibrosis quística y 17 bronquiectasias de otras etiologías). No había diferencias significativas en las variables demográficas entre ambos grupos. En el momento del trasplante la función pulmonar mostraba grave obstruc-ción bronquial (volumen espiratorio forzado en el primer segundo: 808 ± 342 ml; capacidad vital forzada: 1.390 ±611 ml) e insuficiencia respiratoria (presión arterial de oxígeno: 52 ± 10 mmHg; presión arterial de anhídrido carbónico: 48 ± 9 mmHg). Sólo la presión arterial de oxígeno fue significa-tivamente inferior en los pacientes con bronquiectasias de etiología diferente de la fibrosis quística. El 91% de los pacientes presentaba colonización de la vía aérea; el germen más frecuente fue Pseudomona spp. (64%), que en un 9% de los casos fue multirresistente. En el postoperatorio inmedia-to se aislaron gérmenes en el 59% de los casos; la mitad de ellos eran los mismos que se habían aislado antes del trasplante. Un año después del trasplante pulmonar, un 34% de los pacientes seguían mostrando colonización bronquial. La supervivencia al año fue del 79% y a los 5 años del 49%, sin diferencias significativas entre los pacientes con fibrosis quística y el resto de las enfermedades supurativas, ni entre los pacientes con o sin colonización por Pseudomonas spp. Sólo 2 pacientes fallecieron por neumonía bacteriana en el primer mes del trasplante pulmonar.

Conclusiones

A pesar de que la colonización de la vía aérea de los pacientes con enfermedad supurativa complica el manejo tras el trasplante pulmonar, los resultados en tér-minos de supervivencia son buenos.

Palabras clave:
Trasplante pulmonar
Bronquiectasias
Fibrosis quística
Pseudomonas
Enfermedad supurativa
Full text is only aviable in PDF
REFERENCES
[1]
E Trulock, L Edwards, D Taylor, M Boucek, P Mohacsi, B Keck, et al.
The registry of the International Society for Heart and Lung Transplantation: nineteenth official report 2003.
J Heart Lung Transplant, 22 (2003), pp. 625-635
[2]
Estadística de la Organización Nacional de Trasplantes.
[3]
MI Barrios.
Infecciones pulmonares por gérmenes multirresistentes.
Rev Patol Respir, 5 (2003), pp. 22-25
[4]
T Egan, F Detterbeck, M Mill, K Gott, J Rea, J McSweeney, et al.
Lung transplantation for cystic fibrosis: effective and durable therapy in a high-risk group.
Ann Thorac Surg, 66 (1998), pp. 337-346
[5]
A de Soyza, L Archer, J Wardle, G Parry, JH Dark, K Gould, et al.
Pulmonary transplantation for cystic fibrosis: pre-transplant recipient characteristics in patients dying of peri-operative sepsis.
J Heart Lung Transplant, 22 (2003), pp. 764-769
[6]
C Chaparro, J Maurer, C Gutiérrez, M Krajden, C Chan, T Winton, et al.
Infection with Burkholderia cepacia in cystic fibrosis.
Am J Respir Crit Care Med, 163 (2001), pp. 43-48
[7]
B Lang, S Aaron, W Ferris, P Hebert, N MacDonald.
Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with multiresistant strains of Pseudomonas aeruginosa.
Am J Respir Crit Care Med, 162 (2000), pp. 2241-2245
[8]
JJ Egan, K Mcneil, B Bookless, K Gould, P Corris, T Higenbottam, et al.
Post-transplantation survival of cystic fibrosis patients infected with Pseudomonas cepacia.
Lancet, 344 (1994), pp. 552-553
[9]
PA Flume, TM Egan, LJ Pardowski, FC Detterberck, JT Thompson, JR Yankaskas.
Infectious complications of lung transplantation. Impact of cystic fibrosis.
Am J Resp Crit Care Med, 149 (1994), pp. 1601-1607
[10]
A de Soyza, L Archer, A McDowell, J Moore, JH Dark, S Elborn, et al.
Lung transplantation for cystic fibrosis; the effect of B. cepacia genomovars on post transplant outcomes.
J Heart Lung Transplant, 20 (2001), pp. 158
[11]
A de Soyza, A McDowell, L Archer, JH Dark, SJ Elborn, E Mahenthiralingam, et al.
Burkholderia cepacia complex genomovars and pulmonary transplantation outcomes in patients with cystic fibrosis.
Lancet, 358 (2001), pp. 1780-1781
[12]
RM Aris, JC Routh, JJ LiPuma, DG Heath, PH Gilligan.
Lung transplantation for cystic fibrosis patients with Burkholderia cepacia complex. Survival linked to genomovar type.
Am J Respir Crit Care Med, 164 (2001), pp. 2102-2106
[13]
E Kerem, J Reisman, M Corey, GJ Canny, H Levison.
Prediction of mortality in patients with cystic fibrosis.
N Engl J Med, 326 (1992), pp. 1187-1191
[14]
T Liou, F Adler, B Cahill, S Fitzsimmons, D Huang, J Hibbs, et al.
Survival effect of lung transplantation among patients with cystic fibrosis.
JAMA, 286 (2001), pp. 2683-2689
[15]
J de Meester, JMA Smits, G Persijn, A Haverich.
Listing for lung transplantation: life expectancy and transplant effect, stratified by type of end-stage lung disease, the Eurotransplant experience.
J Heart Lung Transplant, 20 (2001), pp. 518-524
[16]
S Charman, L Sharples, K McNeil, J Wallwork.
Assessment of survival benefit after lung transplantation by patient diagnosis.
J Heart Lung Transplant, 21 (2002), pp. 226-232
[17]
The International Society for Heart and Lung Transplantation, the American Thoracic Society, the American Society of Transplant Physicians, the European Respiratory Society.
International guidelines for the selection of lung transplant candidates.
Transplantation, 66 (1998), pp. 951-956
[18]
Grupo de Trabajo de la SEPAR.
Normativa sobre trasplante pulmonar, Ediciones Doyma, (2001),
Copyright © 2005. Sociedad Española de Neumología y Cirugía Torácica (SEPAR)
Archivos de Bronconeumología
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?